Amneal Pharmaceuticals (AMRX) revenue

Revenue · fiscal 2025
$3.02B

Amneal Pharmaceuticals (AMRX) reported revenue of $3.02B in fiscal 2025 (the year ended December 31, 2025). That is 8.0% higher than the $2.79B of fiscal 2024. Figures as of 18 Nov 2026, 09:33 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$3.02B
Change on fiscal 2024
+8.0%
Growth, 5 years
+8.7% a year
Highest on record
$3.02Bfiscal 2025
Lowest on record
$1.02Bfiscal 2016
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Amneal Pharmaceuticals revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 8.7% a year. Across the 10 fiscal years on record (2016–2025), the highest was $3.02B in fiscal 2025 and the lowest $1.02B in fiscal 2016.

History · 10 fiscal years

Revenue by fiscal year

Amneal Pharmaceuticals revenue, year by year

Amneal Pharmaceuticals (AMRX) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$3.02B 8.0% up
2024$2.79B 16.7% up
2023$2.39B 8.2% up
2022$2.21B 5.7% up
2021$2.09B 5.1% up
2020$1.99B 22.5% up
2019$1.63B 2.2% down
2018$1.66B 60.9% up
2017$1.03B 1.5% up
2016$1.02B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Amneal Pharmaceuticals and comparable companies
CompanyRevenueFiscal year
Cytokinetics CYTK$88.04M2025
Bausch + Lomb BLCO$5.10B2025
Amneal Pharmaceuticals AMRX$3.02B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AMRX

Amneal Pharmaceuticals, figure by figure

Amneal Pharmaceuticals (AMRX) overview: price, valuation and scorecardAll health care companies by market value

Amneal Pharmaceuticals revenue: questions and answers

What is Amneal Pharmaceuticals's revenue?

Amneal Pharmaceuticals (AMRX) reported revenue of $3.02B in fiscal 2025 (the year ended December 31, 2025). That is 8.0% higher than the $2.79B of fiscal 2024.

What is the growth rate of Amneal Pharmaceuticals's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 8.7% a year.

What are the highest and lowest revenue figures on record for Amneal Pharmaceuticals?

Across the 10 fiscal years on record (2016–2025), the highest was $3.02B in fiscal 2025 and the lowest $1.02B in fiscal 2016.

How is Amneal Pharmaceuticals's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Amneal Pharmaceuticals it is on record here for 10 fiscal years, 2016 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Amneal Pharmaceuticals (AMRX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/AMRX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.